Comments to the editor on "outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: A Markov model"

Value in Health

Volumn 8, Issue 2, 2005, Pages 175-176

  Clewell, Jerry D ^a   Baker, Robert W ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; RISPERIDONE;

DATA ANALYSIS; DIABETES MELLITUS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; LETTER; MODEL; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; PUBLICATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 17144369836     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2005.08204.x     Document Type: Letter

References (11)

1. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother 2003;37:625-30.
2. Rascati K, Johnsrud MT, Crismon LM, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid patients. Pharmacoeconomics 2003;21: 683-97.
3. Zhao Z, Damler RM, Jackson EA, Ramsey JL. Atypical antipsychotic treatment adherence and persistence in a state Medicaid program. Paper presented at: Institute for Psychiatric Services Annual Meeting, October 2003, Boston, MA.
4. Zhao Z, Tunis SL, Lage MJ. Medication treatment patterns following initiation on Olanzapine versus risperidone: a retrospective analysis. Clin Drug Invest 2002;22:741-9.
5. Gibson P, Damler R, Jackson L, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health 2004;7:22-35.
6. Zhu B, Ascher-Svanum H, Faries D, et al. Differences among antipsychotics in the time to all-cause drug discontinuation: results from a longitudinal naturalistic study of schizophrenia. Paper presented at: American Psychiatric Association Annual Meeting, May 17-22, 2003, San Francisco, CA.
7. Haro JM, Novick D, Belger M, et al. Continuation of antipsychotic treatment in the outpatient setting: 12-month results from the schizophrenia outpatient health outcomes (SOHO) study. Presented at the 157th Annual Meeting of the American Psychiatric Association (APA), May 1-6, 2004, New York, NY.
8. Sclar D, Robison LM, Skaer TL, et al. Cost and use patterns for atypical antipsychotics among Medicaid patients. Poster (NR226) presented at: American Psychiatric Association Annual Meeting, 2003, San Francisco, CA.
9. Zhao Z. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia. Curr Med Res Opin 2004;20:1039-48.
10. Citrome LL, Jaffe AB. Relationships of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003;37:1849-57.
11. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74.